Filtered By:
Education: Academia
Management: Partnerships

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 22 results found since Jan 2013.

Academic-industry Collaborations in Translational Stroke Research
Abstract Academic-industry collaborations are an emerging format of translational stroke research. Next to classic contract research models, a multitude of collaboration models has been developed, some of which even allowing for multinational or intercontinental research programs. This development has recently been paralleled by first successful attempts to overcome the translational stroke research road block, such as the unprecedented success of novel endovascular approaches or the advent of the multicenter preclinical trial concept. While the first underlines the role of the industry as a major innovation drive...
Source: Translational Stroke Research - June 13, 2016 Category: Neurology Source Type: research

UCLA, USC get $2M to develop stroke center network in Southland
Stroke is the second leading cause of death in Los Angeles County and the fourth in the U.S. In order to cut those numbers, it's imperative that new treatments be developed and refined for stroke prevention, acute therapy and recovery after stroke.   Now, a three-way partnership between the UCLA Stroke Center at Ronald Reagan UCLA Medical Center, the USC Comprehensive Stroke and Cerebrovascular Center at Keck Medicine of USC, and UC Irvine has been awarded a $2 million grant from the National Institutes of Health to address these three stroke priorities.   Together, the three universities will form the Los A...
Source: UCLA Newsroom: Health Sciences - October 15, 2013 Category: Universities & Medical Training Source Type: news

UCLA, partners get $11M to develop stroke-prevention programs for minority populations
UCLA researchers and their partners across Los Angeles County have been awarded an $11 million federal grant to fund research on community-based interventions aimed at reducing the higher rates of stroke and death from stroke among disadvantaged Hispanics, African Americans and Asian Americans.   Research has shown that stroke risk can be substantially lowered by increasing physical activity, controlling blood pressure, adopting a healthy diet, quitting smoking, lowering cholesterol and, for certain individuals, taking medication like aspirin.   However, the underserved populations targeted by this research progr...
Source: UCLA Newsroom: Health Sciences - May 1, 2013 Category: Universities & Medical Training Source Type: news

Bayer Forms Collaboration with Academic and Governmental Institutions for Rivaroxaban Study in Patients with a recent Embolic Stroke of Undetermined Source (for specialized target groups only)
Embolic stroke of undetermined source is caused by a blood clot, and affects approximately 300,000 people each year in North America and Europe / Phase III NAVIGATE ESUS study will investigate once-daily rivaroxaban for the secondary prevention of stroke in approximately 7,000 patients / Indication-seeking trial will be conducted in partnership with Population Health Research Institute and Canadian Stroke Prevention Intervention Network
Source: Bayer Company News - January 27, 2015 Category: Pharmaceuticals Source Type: news

27.01.15: Not intended for U.S. and UK Media
Bayer Forms Collaboration with Academic and Governmental Institutions for Rivaroxaban Study in Patients with a recent Embolic Stroke of Undetermined SourceEmbolic stroke of undetermined source is caused by a blood clot, and affects approximately 300,000 people each year in North America and Europe / Phase III NAVIGATE ESUS study will investigate once-daily rivaroxaban for the secondary prevention of stroke in approximately 7,000 patients / Indication-seeking trial will be conducted in partnership with Population Health Research Institute and Canadian Stroke Prevention Intervention Networkmehr ...
Source: Bayer IR Newsfeed: Events - January 27, 2015 Category: Pharmaceuticals Source Type: news

An Integrated Approach for Vascular Health: A Call to Action
Publication date: Available online 6 November 2014 Source:Canadian Journal of Cardiology Author(s): Blair J. O'Neill , Shadab N. Rana , Vincent Bowman Vascular diseases such as stroke, myocardial infarction, most causes of heart failure, dementia, peripheral arterial disease, certain kidney, and many lung and eye conditions are a result of disorders in the blood vessels (large and small) throughout the entire human body. Vascular diseases are the leading cause of preventable death and disability in Canada 1 . Most vascular diseases share common risk factors (high blood pressure, diabetes, dyslipidemia and obesity), which...
Source: Canadian Journal of Cardiology - November 7, 2014 Category: Cardiology Source Type: research

Redivus Health Launches State of Kansas Initiative in Partnership With The University of Kansas Health System
OLATHE, Kan. & KANSAS CITY, Kan. (Dec. 11, 2017) — Redivus Health announced today it will partner with The University of Kansas Health System to roll out the Redivus mobile clinical decision support platform to Kansas hospitals and Emergency Medical Services (EMS) providers starting this month. The initiative builds on a pilot program started earlier this year. “The goal of the Kansas Heart and Stroke Collaborative is to improve the care and outcomes of rural Kansans with heart attacks and strokes. Our rural health system partners helped develop the protocols and tools to implement evidenced-based guidelines,” sa...
Source: JEMS Administration and Leadership - December 11, 2017 Category: Emergency Medicine Authors: Revidus Health Tags: Administration and Leadership Industry News Source Type: news

2019 Cochrane-REWARD Prize winners announced
We are pleased to announce the winners – one first place and two runners-up – of this year’s Cochrane-REWARD Prize. The Cochrane-REWARD Prize recognizes successful local or pilot initiatives that have potential to reduce research waste globally if scaled up. Cochrane has funded the prize annually since it began in 2017.The prize ceremony took place on Wednesday 9 October at the International Clinical Trials Methodology Conference in Brighton, UK. Dr Joan Marsh, Deputy Editor of The Lancet Psychiatry and member of the prize committee, was there to hand out the prizes. During the conference, each recipient also had the...
Source: Cochrane News and Events - October 18, 2019 Category: Information Technology Authors: Lydia Parsonson Source Type: news

Diane Stephenson
is a neuroscientist by training with 30 years  combined experience in academic neuroscience and drug discovery.  She is passionate about translational science and has a long time  dedication to the discovery of therapies to treat diseases of the nervous system. Diane received her undergraduate degree in Biochemistry at University of California, Santa Barbara and her Ph.D. in Medical Neurobiology from Indiana University. In her academic career, Diane focused her research on Amyotrophic Lateral Sclerosis and Alzheimer's disease while in industry she focused on drug discovery for Alzheimer's disease, stroke and Parkinson'...
Source: PHRMA - November 5, 2013 Category: Pharmaceuticals Authors: Leah Source Type: news

Diane Stephenson, Ph.D.
EVP, Coalition Against Major DiseasesDiane Stephenson is a neuroscientist by training with 30 years  combined experience in academic neuroscience and drug discovery.  She is passionate about translational science and has a long time  dedication to the discovery of therapies to treat diseases of the nervous system. Diane received her undergraduate degree in Biochemistry at University of California, Santa Barbara and her Ph.D. in Medical Neurobiology from Indiana University. In her academic career, Diane focused her research on Amyotrophic Lateral Sclerosis and Alzheimer's disease while in industry she focused on drug dis...
Source: PHRMA - November 5, 2013 Category: Pharmaceuticals Authors: Leah Source Type: news

More Coca-Cola Ties Seen Inside U.S. Centers For Disease Control
In June, Dr. Barbara Bowman, a high-ranking official within the Centers for Disease Control and Prevention, unexpectedly departed the agency, two days after information came to light indicating that she had been communicating regularly with - and offering guidance to - a leading Coca-Cola advocate seeking to influence world health authorities on sugar and beverage policy matters. Now, more emails suggest that another veteran CDC official has similarly close ties to the global soft drink giant. Michael Pratt, Senior Advisor for Global Health in the National Center for Chronic Disease Prevention and Health Promotion at the...
Source: Science - The Huffington Post - August 1, 2016 Category: Science Source Type: news

The Importance of Talent and Chemistry in New Patient-First Business Models
Forward-thinking life sciences companies are shifting to new patient-centered business models, leaving the traditional volume-first approach behind. This move has tremendous implications, not only for patients but also for the current workforce and future talent: life sciences companies need to design new roles and rethink their talent strategies, including the ways they recruit, train, motivate and retain the best teams.The shift from volume to valueThe historical model in life sciences has been based on selling products, where more was better - more products, more market share and then more profits. Value-based reimburse...
Source: EyeForPharma - August 12, 2016 Category: Pharmaceuticals Authors: Jeff Elton Source Type: news

Tau Imaging Among Breakthroughs Advancing the Fight against Alzheimer ' s
Worldwide,  nearly44 million  people now have Alzheimer ' s disease (AD) or related dementia, making these conditions the  top cause of disabilities in later life. The biopharma industry has invested billions of dollars into research to treat and prevent AD1, yet this work has faced many obstacles, including difficulty identifying biomarkers, tracking the disease ’s progress in the brain, and recruiting patients to trials while they are still asymptomatic. But in recent years, we’ve begun to see breakthroughs that is driving our research in new directions. Many of these accomplishments were highlighted at the Alzh...
Source: EyeForPharma - September 21, 2016 Category: Pharmaceuticals Authors: Olga Uspenskaya-Cadoz Source Type: news